Magnus Persson, MD PhD

Chairman of the Board

Magnus Persson is a Physician and an associate Professor in Physiology at the Karolinska Institutet in Stockholm. Magnus has 15 years of Partner level experience from Venture Capital and has been a Partner in two Life Sciences Venture Capital firms, one with its base in Sweden and with global reach and one in The Bay Area in California. Magnus has a long experience in medicine, life sciences and biotech financing. He has led development teams of Phase II and III programs in the Pharmaceutical Industry. He has founded and led private as well as public biotech and medtech companies as Chairman of the Board and Director in Europe and USA. All in all, he has more than 90 Board years in the life science industry and has been involved in a dozen IPOs.

Kjell Stenberg, PhD

Kjell Stenberg, PhD served as Chief Operating Officer of Medwell Capital Corp. (also known as BioMS Medical Corp.) from November 17, 2005 to October 5, 2010. Previously, Dr. Stenberg served as Chief Executive Officer of Combio A/S. From 1975 to 2000, Dr. Stenberg served as Senior Researcher and Manager at Astra/AstraZeneca, where he was instrumental in bringing various drugs to market in the capacity of Director of Research or Director of Development.

Stephan Christgau, PhD

Stephan Christgau, PhD joined Novo A/S in September 2007 as Investment Director of Novo Seeds. Prior to joining Novo Seeds, Dr. Christgau was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. Previously, Dr. Christgau has worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S. Dr. Christgau is the author of more than 60 scientific publications and inventor on more than 30 patent families.

Jasper Bos, PhD

Jasper Bos is Director with Merck Serono Ventures, the corporate venture capital fund of Merck Serono SA. Prior to joining Merck Serono SA, Dr. Bos served as Investment Manager at IFHA, a growth capital fund backed by Dutch institutional investors and Goldman Sachs. He was instrumental in the founding and capital raise of IFHA and negotiated and managed investments in emerging economies in the healthcare and insurance sectors. Before joining IFHA, he worked as Health Economics and Strategy Manager at the Netherlands Vaccine Institute. Dr. Bos holds a PhD. in Pharmacy from the University of Groningen, the Netherlands. He has published over 30 articles on vaccines, public health and health economics.

Ulf Nilsson, PhD

Ulf J. Nilsson, PhD, is a professor in organic chemistry at Lund University, Sweden. He has more than twenty year of experience in organic and medicinal chemistry and has pioneered the field of developing small-molecule galectin inhibitors. He is the author of more than 90 original scientific publications and an inventor on more than 10 patents families.

Søren Lemonius, MSc

Søren Lemonius partner at Sunstone Capital and has previously spent 10+ years in corporate management. During five years as CTO at Danionics, He participated in developing the company from a 30 employee technology company to a €27+ million, 300+ employees, product selling, listed company. He was responsible for releasing three new product generations. Before joining Danionics, Mr. Lemonius was Innovation Manager at FOSS Analytical, a private, €130+ million developer and producer of analytical equipment. Søren established and developed FOSS’s Innovation Center as a “First Responder” to new project and product opportunities. Søren also serves on the board of Atonomics A/S, Biomonitor A/S, TD Vaccine A/S and Nuevolution A/S.

Carsten Schou, PhD

Carsten Schou is General Partner at SEED Capital Denmark. Previously, Dr. Schou was Director of Research at ALK-Abelló A/S and Partner in Danske Private Equity Life Science. He has a PhD in immunology and more than 10 years of operational experience in the pharmaceutical industry. He has held senior management positions in the biotech industry as well as cofounded two biotech companies. Dr. Schou serves on a number of boards within the Life Sciences sector.